GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Cash Flow from Operations

Arch Biopartners (TSXV:ARCH) Cash Flow from Operations : C$-1.78 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Arch Biopartners's Cash Receipts from Operating Activities was C$0.00 Mil. Its Cash Payments was C$-0.50 Mil. Its Dividends Paid was C$0.00 Mil. Its Dividends Received was C$0.00 Mil. Its Interest Paid was C$-0.05 Mil. Its Interest Received was C$0.00 Mil. Its Taxes Refund Paid was C$0.00 Mil. And its Cash Flow from Others was C$0.00 Mil. In all, Arch Biopartners's Cash Flow from Operations for the three months ended in Dec. 2023 was C$-0.55 Mil.


Arch Biopartners Cash Flow from Operations Historical Data

The historical data trend for Arch Biopartners's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Cash Flow from Operations Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.81 -1.91 -2.98 0.48 -0.23

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.95 0.57 -0.86 -0.55

Arch Biopartners Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Arch Biopartners's Cash Flow from Operations for the fiscal year that ended in Sep. 2023 is calculated as:

Arch Biopartners's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Biopartners  (TSXV:ARCH) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Arch Biopartners's cash receipts from operating activities for the three months ended in Dec. 2023 was C$0.00 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$-0.50 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$-0.05 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$0.00 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Arch Biopartners's cash payments for the three months ended in Dec. 2023 was C$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Arch Biopartners's cash flow from others for the three months ended in Dec. 2023 was C$0.00 Mil.


Arch Biopartners Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

Arch Biopartners (TSXV:ARCH) Headlines

From GuruFocus

Arch Resources: The Windfall Will Not Last

By Rupert Hargreaves 10-10-2022